Lancet neurology
-
Comparative Study
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.
Results of previous studies have shown associations between PET imaging of amyloid plaques and amyloid-β pathology measured at autopsy. However, these studies were small and not designed to prospectively measure sensitivity or specificity of amyloid PET imaging against a reference standard. We therefore prospectively compared the sensitivity and specificity of amyloid PET imaging with neuropathology at autopsy. ⋯ Avid Radiopharmaceuticals.
-
Intracerebral haemorrhage accounts for about 10-15% of all strokes and is associated with high mortality and morbidity. No successful phase 3 clinical trials for this disorder have been completed. ⋯ Several therapeutic targets have subsequently been identified that are now being pursued in clinical trials. Many clinical trials have been based on limited preclinical data, and guidelines to justify taking preclinical results to the clinic are needed.
-
Many people who suffer from primary headache (ie, headache without an identifiable cause) are resistant or intolerant to available drugs. During the past decade, central and peripheral neurostimulation procedures have been investigated in such individuals--up to now, about 1200 worldwide. ⋯ Nonetheless, occipital nerve stimulation and deep brain stimulation of the posterior hypothalamus seem to be effective in people with chronic cluster headache, and occipital nerve stimulation is promising in chronic migraine. Trial data for other techniques are scarce, but external and minimally invasive approaches should be privileged in future studies.
-
Review
Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment.
Dementia is one of the most common and important aspects of Parkinson's disease and has consequences for patients and caregivers, and has health-related costs. Mild cognitive impairment is also common and frequently progresses to dementia. ⋯ Rivastigmine is the only licensed treatment for dementia in Parkinson's disease, but emerging evidence suggests that memantine might also be useful. Whether these or other treatments can delay the progression from mild cognitive impairment to dementia in Parkinson's disease is a key research question.
-
Many people with epilepsy in low-income countries do not receive appropriate biomedical treatment. This epilepsy treatment gap might be caused by patients not seeking biomedical treatment or not adhering to prescribed antiepileptic drugs (AEDs). We measured the prevalence of and investigated risk factors for the epilepsy treatment gap in rural Kenya. ⋯ Wellcome Trust.